patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_121626 | REC_0005701 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.1 | 56 | male | 0 | 32 | 6 | 5 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:58.255233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371202 | REC_0005702 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 16.6 | 70 | female | 2 | 22 | 4.4 | 2 | osimertinib 80 mg daily | 19.2 | true | MSI-H | 2026-03-15T05:35:58.255465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829506 | REC_0005703 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 8.9 | 71 | female | 2 | 5 | 3.2 | 1 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:58.255693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680098 | REC_0005704 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 12.1 | 58 | female | 0 | 18 | 4.1 | 1 | sotorasib 960 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:58.255928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769590 | REC_0005705 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 9.2 | 70 | male | 2 | 21 | 3.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.4 | true | MSS | 2026-03-15T05:35:58.256240+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791077 | REC_0005706 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.3 | 71 | female | 3 | 26 | 2.9 | 7 | sotorasib 960 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:58.256482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520824 | REC_0005707 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6 | 59 | male | 0 | 45 | 3.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.6 | false | MSS | 2026-03-15T05:35:58.256717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182038 | REC_0005708 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 18.2 | 69 | female | 1 | 23 | 7 | 4 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:58.257009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676304 | REC_0005709 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 9.2 | 73 | female | 2 | 20 | 5.7 | 5 | alectinib 600 mg BID | 12.3 | true | MSS | 2026-03-15T05:35:58.257241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439118 | REC_0005710 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.3 | 72 | female | 1 | 17 | 6.5 | 2 | sotorasib 960 mg daily | 24.7 | false | MSS | 2026-03-15T05:35:58.257473+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963158 | REC_0005711 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 10.6 | 63 | female | 1 | 20 | 3.3 | 1 | alectinib 600 mg BID | 28.5 | true | MSI-H | 2026-03-15T05:35:58.257710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903038 | REC_0005712 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 16.8 | 69 | female | 1 | 13 | 5.9 | 6 | sotorasib 960 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:58.257940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680472 | REC_0005713 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 9 | 65 | male | 0 | 2 | 6.2 | 1 | entrectinib 600 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:58.258174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480401 | REC_0005714 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 15.7 | 63 | male | 1 | 21 | 5.6 | 6 | alectinib 600 mg BID | 7.9 | true | MSS | 2026-03-15T05:35:58.258406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214463 | REC_0005715 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 12.7 | 79 | female | 2 | 20 | 5.7 | 2 | alectinib 600 mg BID | 14.7 | true | MSI-H | 2026-03-15T05:35:58.258638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339336 | REC_0005716 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.8 | 75 | male | 2 | 23 | 5 | 6 | sotorasib 960 mg daily | 11 | false | MSS | 2026-03-15T05:35:58.258875+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782893 | REC_0005717 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 8.8 | 56 | male | 1 | 27 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.5 | true | MSS | 2026-03-15T05:35:58.259106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602944 | REC_0005718 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 9 | 76 | female | 2 | 8 | 4.4 | 8 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:58.259337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136859 | REC_0005719 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.5 | 69 | male | 1 | 84 | 6.8 | 4 | pembrolizumab 200 mg q3w | 15.2 | true | MSS | 2026-03-15T05:35:58.259569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800977 | REC_0005720 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.6 | 73 | female | 2 | 15 | 5.6 | 6 | alectinib 600 mg BID | 7.2 | true | MSI-H | 2026-03-15T05:35:58.259874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447457 | REC_0005721 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 9.1 | 63 | male | 1 | 12 | 7 | 1 | sotorasib 960 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:58.260182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430989 | REC_0005722 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 12.8 | 60 | female | 1 | 10 | 4.5 | 7 | entrectinib 600 mg daily | 23.6 | false | MSI-H | 2026-03-15T05:35:58.260423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631499 | REC_0005723 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.5 | 72 | female | 2 | 40 | 5.9 | 9 | carboplatin + paclitaxel + pembrolizumab | 4.6 | false | MSS | 2026-03-15T05:35:58.260659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928187 | REC_0005724 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 11.5 | 75 | female | 2 | 18 | 7 | 6 | entrectinib 600 mg daily | 15.9 | false | MSS | 2026-03-15T05:35:58.260896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538240 | REC_0005725 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 8.2 | 74 | female | 1 | 18 | 4.7 | 2 | sotorasib 960 mg daily | 19.4 | false | MSS | 2026-03-15T05:35:58.261125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525189 | REC_0005726 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 11.2 | 78 | female | 2 | 21 | 6.2 | 2 | sotorasib 960 mg daily | 15.7 | false | MSI-H | 2026-03-15T05:35:58.261362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492304 | REC_0005727 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 9.6 | 72 | female | 1 | 17 | 6.8 | 2 | alectinib 600 mg BID | 21.3 | true | MSS | 2026-03-15T05:35:58.261590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302928 | REC_0005728 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 6.5 | 67 | female | 0 | 12 | 5.2 | 2 | pembrolizumab 200 mg q3w | 27.4 | false | MSS | 2026-03-15T05:35:58.261823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975234 | REC_0005729 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 17 | 68 | female | 0 | 15 | 6.7 | 3 | alectinib 600 mg BID | 15.4 | true | MSS | 2026-03-15T05:35:58.262057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344587 | REC_0005730 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 10.3 | 63 | male | 0 | 24 | 5.6 | 2 | sotorasib 960 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:58.262292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986701 | REC_0005731 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 17.8 | 63 | female | 0 | 17 | 4.7 | 2 | osimertinib 80 mg daily | 8.1 | false | MSS | 2026-03-15T05:35:58.262526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889800 | REC_0005732 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.7 | 70 | female | 2 | 13 | 4.7 | 2 | pembrolizumab 200 mg q3w | 22.3 | false | MSS | 2026-03-15T05:35:58.262754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_971695 | REC_0005733 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 16.5 | 70 | female | 1 | 16 | 4 | 1 | alectinib 600 mg BID | 21.9 | true | MSS | 2026-03-15T05:35:58.262985+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667382 | REC_0005734 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 5.9 | 57 | male | 1 | 9 | 5.9 | 1 | alectinib 600 mg BID | 25.5 | false | MSS | 2026-03-15T05:35:58.263257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844342 | REC_0005735 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 4 | 76 | female | 1 | 64 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.7 | false | MSS | 2026-03-15T05:35:58.263494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986161 | REC_0005736 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 15.4 | 64 | female | 1 | 16 | 5.5 | 2 | alectinib 600 mg BID | 6 | true | MSI-H | 2026-03-15T05:35:58.263728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398213 | REC_0005737 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 13 | 11.4 | 77 | female | 2 | 19 | 4.6 | 5 | sotorasib 960 mg daily | 20.1 | false | MSI-H | 2026-03-15T05:35:58.263964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963153 | REC_0005738 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.7 | 90 | female | 1 | 10 | 4.9 | 4 | alectinib 600 mg BID | 8.1 | true | MSI-H | 2026-03-15T05:35:58.264297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286785 | REC_0005739 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 18.9 | 54 | female | 0 | 13 | 6.2 | 3 | osimertinib 80 mg daily | 5.3 | false | MSI-H | 2026-03-15T05:35:58.264538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865531 | REC_0005740 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.2 | 58 | female | 1 | 19 | 5 | 1 | entrectinib 600 mg daily | 20.6 | true | MSS | 2026-03-15T05:35:58.264774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218904 | REC_0005741 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 17.8 | 67 | female | 1 | 18 | 4.8 | 4 | osimertinib 80 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:58.265008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764772 | REC_0005742 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.1 | 50 | male | 0 | 54 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:35:58.265239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257490 | REC_0005743 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 8.6 | 56 | female | 0 | 19 | 6 | 4 | sotorasib 960 mg daily | 15.4 | false | MSS | 2026-03-15T05:35:58.265472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867962 | REC_0005744 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 4.9 | 72 | female | 2 | 9 | 4.5 | 4 | entrectinib 600 mg daily | 13.6 | false | MSS | 2026-03-15T05:35:58.265697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178540 | REC_0005745 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 9.9 | 71 | female | 1 | 14 | 6.5 | 9 | alectinib 600 mg BID | 11 | true | MSS | 2026-03-15T05:35:58.265930+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865099 | REC_0005746 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 33 | 11.4 | 52 | male | 0 | 8 | 6.4 | 2 | alectinib 600 mg BID | 21.7 | true | MSS | 2026-03-15T05:35:58.266163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131367 | REC_0005747 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.4 | 58 | male | 1 | 56 | 7.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:35:58.266441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872948 | REC_0005748 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 15.8 | 64 | male | 1 | 12 | 6.2 | 5 | alectinib 600 mg BID | 12.1 | false | MSS | 2026-03-15T05:35:58.266679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293279 | REC_0005749 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 16 | 71 | female | 2 | 23 | 5.5 | 3 | osimertinib 80 mg daily | 17.7 | true | MSS | 2026-03-15T05:35:58.266914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643957 | REC_0005750 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.2 | 75 | female | 2 | 14 | 4.8 | 7 | entrectinib 600 mg daily | 16.4 | false | MSI-H | 2026-03-15T05:35:58.267149+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285612 | REC_0005751 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.9 | 65 | female | 0 | 60 | 6.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.5 | true | MSS | 2026-03-15T05:35:58.267384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522022 | REC_0005752 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10 | 70 | female | 0 | 15 | 5.9 | 7 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:58.267617+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440388 | REC_0005753 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.2 | 66 | female | 0 | 67 | 5.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:35:58.267843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144889 | REC_0005754 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.8 | 80 | female | 1 | 19 | 5.8 | 6 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:58.268113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338477 | REC_0005755 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.4 | 49 | male | 0 | 64 | 6.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:35:58.268353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714561 | REC_0005756 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 12.5 | 64 | male | 0 | 17 | 3.5 | 2 | pembrolizumab 200 mg q3w | 9 | true | MSI-H | 2026-03-15T05:35:58.268600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663863 | REC_0005757 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 12.3 | 67 | female | 1 | 13 | 5.9 | 9 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:58.268839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_665329 | REC_0005758 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 8.2 | 79 | female | 0 | 52 | 4.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 8.2 | true | MSS | 2026-03-15T05:35:58.269068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352315 | REC_0005759 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 3.9 | 58 | male | 1 | 45 | 7.3 | 0 | pembrolizumab 200 mg q3w | 8.1 | true | MSS | 2026-03-15T05:35:58.269301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776102 | REC_0005760 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 18.5 | 79 | female | 2 | 11 | 6.5 | 2 | osimertinib 80 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:35:58.269589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777809 | REC_0005761 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 9.3 | 68 | female | 0 | 19 | 3 | 5 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:35:58.269823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390137 | REC_0005762 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 17.9 | 65 | female | 1 | 10 | 4.4 | 6 | entrectinib 600 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:58.270060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566177 | REC_0005763 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 14.8 | 63 | male | 1 | 18 | 4.9 | 4 | pembrolizumab 200 mg q3w | 9 | false | MSS | 2026-03-15T05:35:58.270297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_953771 | REC_0005764 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.9 | 65 | female | 1 | 15 | 4.1 | 1 | osimertinib 80 mg daily | 5.5 | false | MSS | 2026-03-15T05:35:58.270532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778285 | REC_0005765 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.7 | 63 | male | 1 | 7 | 3.9 | 4 | alectinib 600 mg BID | 7.2 | true | MSS | 2026-03-15T05:35:58.270769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721282 | REC_0005766 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.3 | 67 | female | 0 | 18 | 5.7 | 6 | entrectinib 600 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:58.270997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848808 | REC_0005767 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.9 | 74 | female | 3 | 7 | 5.5 | 4 | alectinib 600 mg BID | 11.6 | false | MSS | 2026-03-15T05:35:58.271233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280710 | REC_0005768 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 14.4 | 78 | female | 3 | 11 | 5.4 | 7 | entrectinib 600 mg daily | 17 | true | MSS | 2026-03-15T05:35:58.271467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692758 | REC_0005769 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 16.1 | 82 | female | 2 | 16 | 4.6 | 5 | sotorasib 960 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:58.271698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130408 | REC_0005770 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 4.7 | 66 | female | 0 | 25 | 6.5 | 4 | pembrolizumab 200 mg q3w | 18.8 | true | MSS | 2026-03-15T05:35:58.271925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303823 | REC_0005771 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 5.8 | 63 | female | 1 | 17 | 6.5 | 6 | entrectinib 600 mg daily | 7.9 | false | MSS | 2026-03-15T05:35:58.272182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792557 | REC_0005772 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.3 | 74 | female | 2 | 67 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.6 | true | MSS | 2026-03-15T05:35:58.272414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947504 | REC_0005773 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 9.6 | 81 | male | 2 | 14 | 3.7 | 3 | alectinib 600 mg BID | 5.4 | false | MSS | 2026-03-15T05:35:58.272693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684958 | REC_0005774 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 13 | 9.9 | 75 | female | 1 | 25 | 3.4 | 0 | entrectinib 600 mg daily | 35 | true | MSS | 2026-03-15T05:35:58.272928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987996 | REC_0005775 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.8 | 61 | female | 1 | 53 | 4.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSS | 2026-03-15T05:35:58.273161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942298 | REC_0005776 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 41 | 5.1 | 75 | female | 1 | 23 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.1 | true | MSS | 2026-03-15T05:35:58.273390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208352 | REC_0005777 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 3.7 | 65 | male | 0 | 60 | 5.8 | 5 | pembrolizumab 200 mg q3w | 13.6 | false | MSS | 2026-03-15T05:35:58.273625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183976 | REC_0005778 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 14.7 | 61 | male | 0 | 9 | 4.3 | 0 | entrectinib 600 mg daily | 26 | true | MSS | 2026-03-15T05:35:58.273861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792315 | REC_0005779 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 36 | 6.5 | 65 | female | 1 | 9 | 5.4 | 6 | sotorasib 960 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:58.274092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510553 | REC_0005780 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 5.3 | 69 | female | 1 | 14 | 4 | 1 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.274320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371253 | REC_0005781 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 12.6 | 62 | male | 1 | 13 | 8.4 | 1 | sotorasib 960 mg daily | 21.4 | true | MSI-H | 2026-03-15T05:35:58.274583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445085 | REC_0005782 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 14.2 | 61 | male | 0 | 8 | 6.7 | 4 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.274821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902956 | REC_0005783 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 5.7 | 73 | female | 2 | 20 | 7.6 | 2 | osimertinib 80 mg daily | 19.9 | true | MSS | 2026-03-15T05:35:58.275100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957278 | REC_0005784 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 14.9 | 70 | male | 2 | 14 | 4.8 | 7 | entrectinib 600 mg daily | 7.1 | false | MSI-H | 2026-03-15T05:35:58.275398+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543169 | REC_0005785 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 7.7 | 77 | female | 4 | 4 | 4.9 | 1 | osimertinib 80 mg daily | 23 | true | MSS | 2026-03-15T05:35:58.275627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_492550 | REC_0005786 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7.7 | 50 | male | 0 | 69 | 3.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.4 | false | MSS | 2026-03-15T05:35:58.275904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189764 | REC_0005787 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.3 | 55 | male | 1 | 11 | 5.3 | 3 | entrectinib 600 mg daily | 15.2 | true | MSS | 2026-03-15T05:35:58.276237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683204 | REC_0005788 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 13.4 | 66 | female | 0 | 9 | 5 | 5 | entrectinib 600 mg daily | 11 | true | MSS | 2026-03-15T05:35:58.276476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916212 | REC_0005789 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 10.8 | 60 | female | 0 | 15 | 4.2 | 2 | alectinib 600 mg BID | 14.6 | false | MSS | 2026-03-15T05:35:58.276715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822418 | REC_0005790 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 29 | 15.3 | 69 | female | 0 | 17 | 5.3 | 0 | entrectinib 600 mg daily | 41.8 | true | MSI-H | 2026-03-15T05:35:58.276948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543426 | REC_0005791 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.1 | 62 | female | 1 | 14 | 4.9 | 4 | entrectinib 600 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:58.277223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669079 | REC_0005792 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 21.1 | 65 | male | 0 | 16 | 5.3 | 7 | sotorasib 960 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:58.277465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407567 | REC_0005793 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 6.4 | 66 | female | 1 | 38 | 5.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 51.4 | false | MSS | 2026-03-15T05:35:58.277699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373174 | REC_0005794 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 2.8 | 74 | female | 2 | 16 | 3.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 33.5 | true | MSS | 2026-03-15T05:35:58.277927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506828 | REC_0005795 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.1 | 68 | female | 0 | 18 | 4.5 | 6 | entrectinib 600 mg daily | 7.8 | true | MSS | 2026-03-15T05:35:58.278161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530462 | REC_0005796 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.1 | 42 | female | 0 | 44 | 3.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 17 | false | MSS | 2026-03-15T05:35:58.278392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501374 | REC_0005797 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 7.9 | 71 | female | 2 | 10 | 7.1 | 1 | osimertinib 80 mg daily | 29.7 | true | MSS | 2026-03-15T05:35:58.278620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405965 | REC_0005798 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 17.2 | 63 | female | 1 | 7 | 4.8 | 7 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:58.278855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836744 | REC_0005799 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.4 | 74 | female | 1 | 18 | 4.6 | 4 | entrectinib 600 mg daily | 14.2 | false | MSS | 2026-03-15T05:35:58.279136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906990 | REC_0005800 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.5 | 71 | female | 1 | 12 | 5.1 | 6 | osimertinib 80 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:35:58.279371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.